Zenas BioPharma says Phase 3 INDIGO trial meets primary endpoint for obexelimab in IgG4-related disease

Zenas BioPharma

Zenas BioPharma

ZBIO

0.00
  • Zenas BioPharma reported additional positive Phase 3 INDIGO results for obexelimab in IgG4-related disease, presented at EULAR 2026 and published in NEJM.
  • The registrational study met its primary endpoint and key secondary endpoints, showing lower disease activity and fewer flares versus placebo.
  • Obexelimab reduced overall steroid use, supporting a steroid-sparing profile with fewer glucocorticoid-related toxicities.
  • Safety was comparable to placebo, strengthening the drug’s risk-benefit profile ahead of potential commercialization.
  • A Biologics License Application for IgG4-related disease was submitted to the FDA in May, setting up a near-term regulatory catalyst.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606021905PRIMZONEFULLFEED9730932) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.